Previous 10 | Next 10 |
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare PR Newswire — Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases ...
Inpixon (INPXV) is expected to report for Q1 2024 Siebert Financial Corp. (SIEB) is expected to report for Q1 2024 Greenwave Technology Solutions Inc. (GWAV) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q1 2024 Gelesis Holdings, Inc. (...
Aditxt (NASDAQ: ADTX) recently provided Evofem Biosciences Inc. (OTCQB: EVFM) $1 million in consideration for reinstating and amending the merger agreement, as amended, between the companies. Aditxt agreed to invest an additional $2.5 million in Evofem by July 1, and the companies are working ...
Evofem Biosciences Announces Financial Results for the First Quarter of 2024 PR Newswire SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) , Evofem ...
2024-05-03 12:57:11 ET More on Aditx Therapeutics Aditxt signs agreement to acquire Appili Therapeutics Financial information for Aditx Therapeutics Read the full article on Seeking Alpha For further details see: Aditxt prices $4.2M private placement
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has entered into securities purchase agreements. The agreements are for the purchase and sale of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock and ...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,1...
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 63.6% to $0.168949 on volume of 119,634,330 shares C3is Inc. (CISS) rose 17.5% to $0.0424 on volume of 56,452,737 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 6.6% to $3.315 on volume...
2024-04-02 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
News, Short Squeeze, Breakout and More Instantly...
ADiTx Therapeutics Inc. Company Name:
ADTX Stock Symbol:
NASDAQ Market:
ADiTx Therapeutics Inc. Website:
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer...
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
Evofem Biosciences Inc. (OTCQB: EVFM) , a company commercializing innovative products to address unmet needs in women's sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem's FDA-approved, hormone-free contra...